Related Experiment Video
Updated: Feb 12, 2026

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis
Published on: October 25, 2024
Hepatocyte growth factor is associated with progression of atherosclerosis: The Multi-Ethnic Study of Atherosclerosis
Elizabeth J Bell1, Paul A Decker2, Michael Y Tsai3
1Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Insights
Higher levels of hepatocyte growth factor (HGF) are linked to increased atherosclerosis progression, including coronary artery calcium and carotid plaque. This finding highlights HGF as a potential biomarker for cardiovascular disease risk.
Area of Science:
- Cardiovascular Science
- Biomarker Discovery
- Medical Research
Background:
- Hepatocyte growth factor (HGF) has been previously linked to cardiovascular diseases like stroke and atherosclerosis.
- The study investigates the association between circulating HGF levels and the progression of atherosclerosis measures.
Purpose of the Study:
- To determine if higher circulating HGF levels are associated with greater progression of coronary artery calcium (CAC) and carotid plaque.
- To explore HGF as a potential clinical biomarker for cardiovascular disease.
Main Methods:
- Utilized data from the Multi-Ethnic Study of Atherosclerosis (MESA) cohort.
- Measured HGF at baseline and followed participants for up to 12 years for atherosclerosis progression.
- Employed mixed-effects models and relative risk regression, adjusting for confounding variables.
Main Results:
- Each standard deviation increase in HGF was associated with a 2.9 Agatston units/year greater CAC progression (p < 0.0001).
- The association between HGF and CAC progression varied significantly by race/ethnicity (p=0.003).
- Each standard deviation increase in HGF was linked to a 4% higher risk of new or additional carotid plaque (p=0.005).
Conclusions:
- Elevated circulating HGF levels are significantly associated with accelerated atherosclerosis progression.
- HGF shows promise as a valuable clinical biomarker for identifying individuals at higher risk of cardiovascular disease.
Background And Aims:
Hepatocyte growth factor (HGF) has previously been associated with risk of stroke, coronary heart disease, and atherosclerosis. We hypothesized that higher circulating HGF is associated with greater progression of measures of atherosclerosis: coronary artery calcium (CAC) and carotid plaque.
Methods:
Participants aged 45-84 years from the prospective cohort study Multi-Ethnic Study of Atherosclerosis had HGF measured at baseline (between 2000 and 2002) and were followed for progression of atherosclerosis for up to 12 years. CAC was measured at all five exams using the Agatston method. Mixed-effects models were used to examine the association of HGF and CAC progression among 6695 participants with available data. Relative risk regression was used to assess the association between HGF and new or additional carotid plaque between exams 1 and 5 in 3400 participants with available data. All point estimates were adjusted for potential confounding variables.
Results:
Each standard deviation higher HGF at baseline was associated with 2.9 Agatston units/year greater CAC progression (95% CI: 1.6-4.2, p < 0.0001), and the magnitude of this association differed by race/ethnicity (p value for interaction by race = 0.003). Each standard deviation higher HGF at baseline was associated with a 4% higher risk of new or additional carotid plaque (95% CI: 1.01-1.08, p = 0.005).
Conclusions:
Higher levels of HGF were significantly associated with greater progression of atherosclerosis in this large and diverse population. Circulating HGF continues to show promise as a potential clinical biomarker for cardiovascular disease.
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis IV: Nursing Management
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH

